Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.

Jacques-Eric Gottenberg 1 Raphaèle Seror 2 Corinne Miceli-Richard 3, 4 Joelle Benessiano 5 Valerie Devauchelle-Pensec 6, 7, 8 Philippe Dieude 9 Jean-Jacques Dubost 10 Anne-Laure Fauchais 11, 12 Vincent Goeb 13 Eric Hachulla 14 Pierre Yves Hatron 14 Claire Larroche 15 Véronique Le Guern 16, 17 Jacques Morel 18 Aleth Perdriger 19 Xavier Puéchal 20 Stephanie Rist 21 Alain Saraux 6, 7, 22 Damien Sene 23 Jean Sibilia 1 Olivier Vittecoq 13 Gaétane Nocturne 24 Philippe Ravaud 25 Xavier Mariette 26
Abstract : OBJECTIVES: To analyze the clinical and immunological characteristics at enrollment in a large prospective cohort of patients with primary Sjögren's syndrome (pSS) and to investigate the association between serum BAFF, beta2-microglobulin and free light chains of immunoglobulins and systemic disease activity at enrollment. METHODS: Three hundred and ninety five patients with pSS according to American-European Consensus Criteria were included from fifteen centers of Rheumatology and Internal Medicine in the "Assessment of Systemic Signs and Evolution of Sjögren's Syndrome" (ASSESS) 5-year prospective cohort. At enrollment, serum markers were assessed as well as activity of the disease measured with the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). RESULTS: Patient median age was 58 (25(th)-75(th): 51-67) and median disease duration was 5 (2-9) years. Median ESSDAI at enrollment was 2 (0-7) with 30.9% of patients having features of systemic involvement. Patients with elevated BAFF, beta2-microglobulin and kappa, lambda FLCS had higher ESSDAI scores at enrollment (4 [2]-[11] vs 2 [0-7], P = 0.03; 4 [1]-[11] vs 2 [0-7], P< 0.0001); 4 [2]-[10] vs 2 [0-6.6], P< 0.0001 and 4 [2-8.2] vs 2 [0-7.0], P = 0.02, respectively). In multivariate analysis, increased beta2-microglobulin, kappa and lambda FLCs were associated with a higher ESSDAI score. Median BAFF and beta2-microglobulin were higher in the 16 patients with history of lymphoma (1173.3(873.1-3665.5) vs 898.9 (715.9-1187.2) pg/ml, P = 0.01 and 2.6 (2.2-2.9) vs 2.1 (1.8-2.6) mg/l, P = 0.04, respectively). CONCLUSION: In pSS, higher levels of beta2-microglobulin and free light chains of immunoglobulins are associated with increased systemic disease activity.
Document type :
Journal articles
Complete list of metadatas

Cited literature [35 references]  Display  Hide  Download

https://hal.univ-brest.fr/hal-00934708
Contributor : Ghislaine Calvez <>
Submitted on : Thursday, February 4, 2016 - 9:26:08 AM
Last modification on : Thursday, July 25, 2019 - 2:24:50 PM
Long-term archiving on : Saturday, November 12, 2016 - 7:44:35 AM

File

journal.pone.0059868.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Jacques-Eric Gottenberg, Raphaèle Seror, Corinne Miceli-Richard, Joelle Benessiano, Valerie Devauchelle-Pensec, et al.. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort.. PLoS ONE, Public Library of Science, 2013, 8 (5), pp.e59868. ⟨http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0059868⟩. ⟨10.1371/journal.pone.0059868⟩. ⟨hal-00934708⟩

Share

Metrics

Record views

675

Files downloads

455